These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 26271829

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.
    Vaccine; 2013 Aug 20; 31(37):3922-7. PubMed ID: 23806241
    [Abstract] [Full Text] [Related]

  • 3. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT, Castellsagué X, Garland SM.
    Vaccine; 2012 Nov 20; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 5. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.
    Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, Rojas R, Herrero R, Hernández-Ávila M.
    Vaccine; 2014 Feb 03; 32(6):725-32. PubMed ID: 24355090
    [Abstract] [Full Text] [Related]

  • 6. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R, Knol MJ, Bogaards JA, van der Klis FR, Meijer CJ, de Melker HE.
    J Infect; 2015 Jul 03; 71(1):61-73. PubMed ID: 25709084
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL, Joura EA.
    BioDrugs; 2011 Oct 01; 25(5):339-43. PubMed ID: 21942919
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF.
    Adv Ther; 2009 Nov 01; 26(11):983-98. PubMed ID: 20024678
    [Abstract] [Full Text] [Related]

  • 15. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
    Medeiros R, Vaz S, Rebelo T, Figueiredo-Dias M.
    Acta Med Port; 2020 Mar 02; 33(3):198-201. PubMed ID: 32130098
    [Abstract] [Full Text] [Related]

  • 16. [Nine-valent HPV vaccine - new generation of HPV vaccine].
    Fait T, Dvořák V, Pilka R.
    Ceska Gynekol; 2015 Dec 02; 80(6):397-400. PubMed ID: 26741152
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
    Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, Romanowski B, Roteli-Martins C, Burlet N, Mihalyi A, Struyf F.
    Expert Rev Vaccines; 2016 Dec 02; 15(3):367-87. PubMed ID: 26902666
    [Abstract] [Full Text] [Related]

  • 19. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
    McCormack PL.
    Drugs; 2014 Jul 02; 74(11):1253-83. PubMed ID: 25022951
    [Abstract] [Full Text] [Related]

  • 20. Cancers attributable to human papillomavirus infection.
    Grulich AE, Jin F, Conway EL, Stein AN, Hocking J.
    Sex Health; 2010 Sep 02; 7(3):244-52. PubMed ID: 20719211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.